Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis

NANot yet recruitingINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

May 31, 2029

Study Completion Date

November 30, 2029

Conditions
Rifampin-resistant TuberculosisDrug-resistant Tuberculosis
Interventions
OTHER

Therapeutic Drug Monitoring for Linezolid

TDM with dose adjustment for trough concentration \>2.5 mg/L LZD

Trial Locations (1)

5206

Nkqubela TB Specialist Hospital, East London

All Listed Sponsors
collaborator

University of Cape Town

OTHER

collaborator

St George's, University of London

OTHER

collaborator

Emory University

OTHER

collaborator

National Department of Health, South Africa

UNKNOWN

collaborator

Columbia University

OTHER

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Albert Einstein College of Medicine

OTHER